Headlines about Bioanalytical Systems (NASDAQ:BASI) have been trending somewhat positive this week, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Bioanalytical Systems earned a coverage optimism score of 0.20 on Accern’s scale. Accern also assigned headlines about the company an impact score of 46.1199496932408 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Bioanalytical Systems (BASI) opened at 1.899 on Friday. Bioanalytical Systems has a 52 week low of $0.60 and a 52 week high of $2.42. The company’s market cap is $15.55 million. The company’s 50-day moving average is $1.70 and its 200-day moving average is $1.36.
Bioanalytical Systems (NASDAQ:BASI) last posted its quarterly earnings results on Monday, May 15th. The company reported $0.05 EPS for the quarter. Bioanalytical Systems had a negative net margin of 8.95% and a negative return on equity of 29.32%. The company had revenue of $6.36 million during the quarter. On average, analysts anticipate that Bioanalytical Systems will post $0.01 EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This piece was first posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another website, it was stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this piece can be accessed at https://stocknewstimes.com/2017/07/21/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-bioanalytical-systems-nasdaqbasi-share-price.html.
Bioanalytical Systems Company Profile
Bioanalytical systems, Inc is an international contract research company providing drug discovery and development services and analytical instruments. The Company operates in two segments: contract research services and research products. The contract research services segment provides research and development support on a contract basis to pharmaceutical companies.
Receive News & Ratings for Bioanalytical Systems Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioanalytical Systems Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
